Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Achieves First Milestone In Parke-Davis Deal; Sets Up US R&D Site

Premium

TEL AVIV--Compugen announced recently that it had met the first milestone in its Leads platform agreement with Parke-Davis ahead of schedule, which activated an undisclosed milestone payment from Parke-Davis, a division of Warner-Lambert.

Leads is a computational biology platform for the modeling and understanding of molecular mechanisms of life. Late last year Parke-Davis became the first of a planned total of three major pharmaceutical company partners for the Leads platform, under a multiyear, multimillion-dollars-per-year agreement.

"The Leads platform is already proving to be a significant factor in furthering our genomic research efforts," said Wendell Wierenga, Parke-Davis senior vice-president of preclinical research, development, and technologies.

As part of its Leads effort, Compugen has just opened a US R&D and partner support center in Jamesburg, NJ. Led by Simchon Faigler, cofounder and vice-president of technology, the new facility will house a multidisciplinary team of research and application scientists focusing on further development of the Leads Platform.

The initial focus for the development of Leads was the extraction of meaningful information, such as new genes, proteins, and splice variants, from expressed and genomic data. Current development efforts include improved chip design and pattern recognition from chip and proteomics expression results.

Filed under

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.